Sanctuary Advisors LLC Acquires Shares of 80,075 Inogen, Inc. (NASDAQ:INGN)

Sanctuary Advisors LLC bought a new position in shares of Inogen, Inc. (NASDAQ:INGNFree Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,075 shares of the medical technology company’s stock, valued at approximately $651,000. Sanctuary Advisors LLC owned about 0.34% of Inogen as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INGN. Meeder Asset Management Inc. bought a new stake in Inogen during the 2nd quarter worth about $30,000. PNC Financial Services Group Inc. increased its holdings in shares of Inogen by 2,918.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock valued at $43,000 after purchasing an additional 7,646 shares in the last quarter. CWM LLC increased its holdings in shares of Inogen by 2,185.9% in the second quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after purchasing an additional 6,339 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Inogen in the 1st quarter worth approximately $81,000. Finally, Pitcairn Co. acquired a new position in Inogen during the 1st quarter worth $86,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research note on Wednesday, August 7th. StockNews.com upgraded Inogen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.00.

Read Our Latest Stock Report on Inogen

Inogen Stock Performance

INGN opened at $9.18 on Tuesday. The company has a fifty day moving average price of $11.02 and a two-hundred day moving average price of $9.12. The firm has a market capitalization of $216.44 million, a PE ratio of -2.22 and a beta of 1.04. Inogen, Inc. has a 52 week low of $4.13 and a 52 week high of $13.33.

Inogen (NASDAQ:INGNGet Free Report) last released its quarterly earnings data on Tuesday, August 6th. The medical technology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.31. The business had revenue of $88.77 million during the quarter, compared to the consensus estimate of $82.50 million. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The firm’s revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.42) earnings per share. Equities analysts forecast that Inogen, Inc. will post -1.92 EPS for the current year.

Inogen Profile

(Free Report)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc. (NASDAQ:INGNFree Report).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.